Showing results (1-10 of 248) with videos related to
Sort By:
Pageof 25
Cancers|July 2, 2021
Drug Development in Tissue-Agnostic IndicationsPauline du Rusquec, Christophe Le TourneauEclinicalmedicine|November 8, 2021
Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysisCamille Moreau Bachelard, Elodie Coquan, Pauline du Rusquec, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 13, 2020
Pseudoprogression and Hyperprogression as New Forms of Response to ImmunotherapyMaxime Frelaut, Pauline du Rusquec, Alexandre de Moura, et al.Bulletin Du Cancer|May 5, 2011
[Prevention strategies for brain metastases from HER2-positive breast cancer]Christophe Le TourneauOncoimmunology|September 16, 2020
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid TumorsMarion Alcantara, Pauline Du Rusquec, Emanuela RomanoTherapeutic Advances in Medical Oncology|June 14, 2017
Pembrolizumab in cervical cancer: latest evidence and clinical usefulnessEdith Borcoman, Christophe Le TourneauCurrent Opinion in Oncology|July 2, 2016
Antibody drug conjugates: the future of chemotherapy?Edith Borcoman, Christophe Le TourneauEuropean Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETESégolène Hescot, Véronique Debien, Julien Hadoux, et al.Expert Opinion on Investigational Drugs|July 12, 2008
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitorChristophe Le Tourneau, Lillian L SiuHematology/Oncology Clinics of North America|November 18, 2008
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neckChristophe Le Tourneau, Eric X ChenPageof 25